Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication

Molecular Therapy

Volumn 16, Issue 1, 2008, Pages 46-51

  Taylor, Jason A ^a   Vojtech, Lucia ^a   Bahner, Ingrid ^b   Kohn, Donald B ^b   Laer, Dorothee Von ^c   Russell, David W ^a   Richard, Robert E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LENTIVIRUS VECTOR; MEMBRANE ASSOCIATED PROTEIN C46; PROTEIN REVM10; SHORT HAIRPIN RNA 1; SPUMA VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CD34 SELECTION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; NONHUMAN; PROTEIN FUNCTION; SPUMA VIRUS; T LYMPHOBLAST; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN SPUMARETROVIRUS; LENTIVIRUS;

EID: 37549003223     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300335     Document Type: Article

References (44)

1. Strayer, DS, Akkina, R, Bunnell, BA, Dropulic, B, Planelles, V, Pomerantz, RJ et al. (2005). Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 11: 823-842.
2. Morgan, RA and Walker, R (1996). Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther 7: 1281-1306.
3. Ranga, U, Woffendin, C, Verma, S, Xu, L, June, CH, Bishop, DK et al. (1998). Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA 95: 1201-1206.
4. Levine, BL, Humeau, LM, Boyer, J, MacGregor, RR, Rebello, T, Lu, X et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 17372-17377.
5. Lunzen, J, Glaunsinger, T, Stahmer, I, Baehr, V, Baum, C, Schilz, A et al. (2007). Transfer of autologous gene-modified T Cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 15: 1024-1033.
6. + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94: 368-371.
7. Amado, RG, Mitsuyasu, RT, Rosenblatt, JD, Ngok, FK, Bakker, A, Cole, S et al. (2004). Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 15: 251-262.
8. + cells. Mol Ther 12: 77-86.
9. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283: 682-686.
10. Evans, JT and Garcia, JV (2000). Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum Gene Ther 11: 2331-2339.
11. Browning, MT, Schmidt, RD, Lew, KA and Rizvi TA (2001). Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions. J Virol 75: 5129-5140.
12. + progenitor cell-derived macrophages. Mol Ther 8: 62-71.
13. Mautino, MR and Morgan, RA (2002). Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther 9: 421-431.
14. Li, MJ, Bauer, G, Michienzi, A, Yee, JK, Lee, NS, Kim, J et al. (2003). Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 8: 196-206.
15. Meiering, CD and Linial, ML (2001). Historical perspective of foamy virus epidemiology and infection. Clin Microbiol Rev 14: 165-176.
16. Wolfe, ND, Switzer, WM, Carr, JK, Bhullar, VB, Shanmugam, V, Tamoufe, U et al. (2004). Naturally acquired simian retrovirus infections in central African hunters. Lancet 363: 932-937.
17. Switzer, WM, Bhullar, V, Shanmugam, V, Cong, ME, Parekh, B, Lerche, NW et al. (2004). Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol 78: 2780-2789.
18. Vassilopoulos, G, Trobridge, G, Josephson, NC and Russell, DW (2001). Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 98: 604-609.
19. Kiem, HP, Allen, J, Trobridge, G, Olson, E, Keyser, K, Peterson, L et al. (2007). Foamy-virus-mediated gene transfer to canine repopulating cells. Blood 109: 65-70.
20. Trobridge, GD and Russell, DW (1998). Helper-free foamy virus vectors. Hum Gene Ther 9: 2517-2525.
21. + cord blood cells. Hum Gene Ther 14 509-519.
22. Josephson, NC, Vassilopoulos, G, Trobridge, GD, Priestley, GV, Wood, BL, Papayannopoulou, T et al. (2002). Transduction of human NOD/ SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 99: 8295-8300.
23. Park, J, Nadeau, P, Zucali, JR, Johnson, CM and Mergia, A (2005). Inhibition of simian immunodeficiency virus by foamy virus vectors expressing siRNAs. Virology 343: 275-282.
24. Malim, MH, Freimuth, WW, Liu, J, Boyle, TJ, Lyerly, HK, Cullen, BR et al. (1992). Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 176: 1197-1201.
25. Lee, NS, Dohjima, T, Bauer, G, Li, H, Li, MJ, Ehsani, A et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20: 500-505.
26. Egelhofer, M, Brandenburg, G, Martinius, H, Schult-Dietrich, P, Melikyan, G, Kunert, R et al. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78: 568-575.
27. Naldini, L, Blomer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
28. Unwalla, HJ, Li, HT, Bahner, I, Li, MJ, Kohn, D and Rossi, JJ (2006). Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol 80: 1863-1873.
29. Salter, RD, Howell, DN and Cresswell, P (1985). Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21: 235-246.
30. Velpandi, A, Nagashunmugam, T, Murthy, S, Cartas, M, Monken, C and Srinivasan, A (1991). Generation of hybrid human immunodeficiency virus utilizing the cotransfection method and analysis of cellular tropism. J Virol 65: 4847-4852.
31. Piller, SC, Dubay, JW, Derdeyn, CA and Hunter, E (2000). Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: Effects on glycoprotein incorporation and infectivity. J Virol 74: 11717-11723.
32. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89: 2259-2267.
33. Bonyhadi, ML, Moss, K, Voytovich, A, Auten, J, Kalfoglou, C, Plavec, I et al. (1997). RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 71: 4707-4716.
34. + hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol Ther 15: 76-85.
35. von Laer, D, Hasselmann, S and Hasselmann, K (2006). Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol 238: 60-77.
36. Hamm, TE, Rekosh, D and Hammarskjold, ML (1999). Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein. J Virol 73: 5741-5747.
37. Li, M, Li, H and Rossi JJ (2006). RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann NY Acad Sci 1082: 172-179.
38. Lohrengel, S, Hermann, F, Hagmann, I, Oberwinkler, H, Scrivano, L, Hoffmann, C et al. (2005). Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 79: 10237-10246.
39. Lu, J, Deeks, SG, Hoh, R, Beatty, G, Kuritzkes, BA, Martin, JN et al. (2006). Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J Acquir Immune Defic Syndr 43: 60-64.
40. Trobridge, G, Vassilopoulos, G, Josephson, N and Russell, DW (2002). Gene transfer with foamy virus vectors. Methods Enzymol 346: 628-648.
41. Trobridge, G, Josephson, N, Vassilopoulos, G, Mac, J and Russell, DW (2002). Improved foamy virus vectors with minimal viral sequences. Mol Ther 6: 321-328.
42. Kiem, HP, Allen, J, Trobridge, G, Olson, E, Keyser, K, Peterson, L et al. (2007). Foamy-virus-mediated gene transfer to canine repopulating cells. Blood 109: 65-70.
43. Hawley, RG, Lieu, FH, Fong, AZ and Hawley, TS (1994). Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1: 136-138.
44. Zufferey, R, Nagy, D, Mandel, RJ, Naldini, L and Trono, D (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.